IVA Stock Forecast 2025-2026
Distance to IVA Price Targets
IVA Price Momentum
10 Quality Stocks Worth Considering Now
Researching Inventiva (IVA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on IVA and similar high-potential opportunities.
Latest IVA Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, IVA has a bullish consensus with a median price target of $11.50 (ranging from $3.00 to $20.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $3.36, the median forecast implies a 242.3% upside. This outlook is supported by 7 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Annabel Samimy at Stifel, projecting a 495.2% upside. Conversely, the most conservative target is provided by Eliana Merle at UBS, suggesting a 10.7% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IVA Analyst Ratings
IVA Price Target Range
Latest IVA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IVA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 4, 2025 | Guggenheim | Etzer Darout | Buy | Maintains | $9.00 |
| Apr 2, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $13.00 |
| Mar 28, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $13.00 |
| Jan 30, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $13.00 |
| Nov 22, 2024 | Stifel | Annabel Samimy | Buy | Maintains | $17.00 |
| Nov 12, 2024 | UBS | Eliana Merle | Neutral | Initiates | $3.00 |
| Oct 15, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $13.00 |
| Sep 26, 2024 | Stifel | Annabel Samimy | Buy | Maintains | $20.00 |
| Sep 26, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $14.00 |
| Sep 26, 2024 | HC Wainwright& Co. | Buy | Maintains | $0.00 | |
| Apr 8, 2024 | Canaccord Genuity | Edward Nash | Buy | Maintains | $20.00 |
| Apr 1, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $22.00 |
| Mar 20, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $22.00 |
| Mar 8, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $22.00 |
| Feb 16, 2024 | Stifel | Annabel Samimy | Buy | Maintains | $25.00 |
| Dec 21, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $24.00 |
| Oct 27, 2023 | Canaccord Genuity | Edward Nash | Buy | Initiates | $12.00 |
| Sep 21, 2023 | Roth MKM | Dylan Dupuis | Buy | Reiterates | $11.00 |
| Sep 1, 2023 | Guggenheim | Etzer Darout | Buy | Reiterates | $12.00 |
| Jul 28, 2023 | HC Wainwright & Co. | Buy | Reiterates | $0.00 |
Inventiva S.A. (IVA) Competitors
The following stocks are similar to Inventiva based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Inventiva S.A. (IVA) Financial Data
Inventiva S.A. has a market capitalization of $321.43M with a P/E ratio of 0.0x. The company generates $16.75M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -27.5% quarter-over-quarter, while maintaining an operating margin of -377.9% and return on equity of +172.7%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Inventiva S.A. (IVA) Business Model
About Inventiva S.A.
Develops oral small molecule therapies.
Inventiva S.A. operates as a clinical-stage biopharmaceutical company, generating revenue through collaborations with global healthcare entities and advancing its drug candidates through clinical trials. The company focuses on diseases with significant unmet medical needs, leveraging its expertise in nuclear receptor biology and proprietary technologies to develop innovative treatments.
Headquartered in France, Inventiva is committed to addressing critical health challenges, particularly in oncology, fibrosis, and genetic diseases. Their work has the potential to transform treatment paradigms for diseases that currently lack effective therapies, making them a key player in the pharmaceutical sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
123
CEO
Mr. Frederic Cren
Country
France
IPO Year
2020
Website
www.inventivapharma.comInventiva S.A. (IVA) Latest News & Analysis
Inventiva filed its 2024 Universal Registration Document with the AMF and its 2024 Annual Report on Form 20-F with the SEC, detailing financials for the year ended December 31, 2024.
The filing of annual reports indicates transparency and compliance, which can enhance investor confidence in Inventiva's financial health and future prospects in the biopharmaceutical sector.
Inventiva has completed patient enrollment in its NATiV3 Phase 3 trial, enrolling 1,009 patients in the main cohort and 410 in the exploratory cohort, exceeding initial targets.
Completion of patient enrollment in a pivotal Phase 3 trial signals progress for Inventiva's treatment, potentially enhancing its market position and influencing stock performance.
Inventiva S.A. (NASDAQ: IVA) will host its Q4 2024 earnings call on March 27, 2025, at 8:00 AM ET, featuring CEO Frédéric Cren and CFO Jean Volatier.
The earnings call indicates potential insights into Inventiva S.A.'s financial health and future prospects, influencing investment decisions and stock valuation.
Inventiva (IVA) reported its 2024 financial results and business update, focusing on therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other unmet medical needs.
Inventiva's financial results and business update indicate its progress in drug development, impacting future revenue potential and investor confidence in the biotech sector.
Inventiva announces the schedule of publication and presentation of its 2024 Full-Year Financial Results
1 month agoInventiva will host a webcast on March 27, 2025, to present its 2024 full-year financial results. The company focuses on developing therapies for metabolic diseases.
The announcement of a webcast for financial results indicates upcoming insights into Inventiva's performance and future outlook, which could influence stock valuation and investor sentiment.
Inventiva announced a preclinical study published in Biomedicine & Pharmacotherapy indicating that lanifibranor may reduce Portal Hypertension, enhancing its portfolio for metabolic diseases.
The publication of positive preclinical results for lanifibranor may enhance Inventiva's credibility and prospects, potentially attracting investors and impacting stock prices positively.
Frequently Asked Questions About IVA Stock
What is Inventiva S.A.'s (IVA) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Inventiva S.A. (IVA) has a median price target of $11.50. The highest price target is $20.00 and the lowest is $3.00.
Is IVA stock a good investment in 2025?
According to current analyst ratings, IVA has 7 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.36. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IVA stock?
Wall Street analysts predict IVA stock could reach $11.50 in the next 12 months. This represents a 242.3% increase from the current price of $3.36. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Inventiva S.A.'s business model?
Inventiva S.A. operates as a clinical-stage biopharmaceutical company, generating revenue through collaborations with global healthcare entities and advancing its drug candidates through clinical trials. The company focuses on diseases with significant unmet medical needs, leveraging its expertise in nuclear receptor biology and proprietary technologies to develop innovative treatments.
What is the highest forecasted price for IVA Inventiva S.A.?
The highest price target for IVA is $20.00 from Annabel Samimy at Stifel, which represents a 495.2% increase from the current price of $3.36.
What is the lowest forecasted price for IVA Inventiva S.A.?
The lowest price target for IVA is $3.00 from Eliana Merle at UBS, which represents a -10.7% decrease from the current price of $3.36.
What is the overall IVA consensus from analysts for Inventiva S.A.?
The overall analyst consensus for IVA is bullish. Out of 7 Wall Street analysts, 7 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $11.50.
How accurate are IVA stock price projections?
Stock price projections, including those for Inventiva S.A., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.